$LUMO
Lumos Pharma Inc Stock $lumo

$lumo Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000112623413000114 Filed on August 08, 2013

Income Statement

Concept	2013 Q3	2013 Q2	2012 Q2
Revenue	$265.0K	$232.0K	$590.0K
YoY Change	-18.96%	-60.68%	9.87%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.300M	$2.300M	$2.200M
YoY Change	64.29%	4.55%	100.0%
% of Gross Profit
Research & Development	$6.125M	$5.037M	$4.740M
YoY Change	28.16%	6.27%	24.9%
% of Gross Profit
Depreciation & Amortization	$200.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	100.0%
% of Gross Profit
Operating Expenses	$8.382M	$7.301M	$6.891M
YoY Change	35.74%	5.95%	39.75%
Operating Profit	-$8.117M	-$7.069M	-$6.301M
YoY Change	38.8%	12.19%	43.4%
Interest Expense	$0.00	$0.00	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$6.000K	-$8.000K	-$8.000K
YoY Change	100.0%	0.0%
Pretax Income	-$8.123M	-$7.077M	-$6.300M
YoY Change	37.68%	12.33%	43.18%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$8.123M	-$7.077M	-$6.309M
YoY Change	38.83%	12.17%	43.58%
Net Earnings / Revenue	-3065.28%	-3050.43%	-1069.32%
Basic Earnings Per Share	-$0.32	-$0.28	-$0.31
Diluted Earnings Per Share	-$0.32	-$0.28	-$0.31
COMMON SHARES
Basic Shares Outstanding	25.70M shares	25.60M shares	20.68M shares
Diluted Shares Outstanding			20.68M shares

Balance Sheet

Concept	2013 Q3	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$52.00M	$59.30M	$31.10M
YoY Change	83.75%	90.68%	217.35%
Cash & Equivalents	$51.96M	$59.04M	$30.33M
Short-Term Investments	$0.00	$200.0K	$700.0K
Other Short-Term Assets	$400.0K	$500.0K	$300.0K
YoY Change	300.0%	66.67%	-81.25%
Inventory
Prepaid Expenses	$405.0K	$535.0K	$254.0K
Receivables
Other Receivables
Total Short-Term Assets	$54.15M	$61.07M	$32.87M
YoY Change	87.23%	85.79%	171.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.738M	$5.942M	$6.265M
YoY Change	10.69%	-5.16%	20.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$6.738M	$5.942M	$6.265M
YoY Change	10.69%	-5.16%	20.48%
TOTAL ASSETS
Total Short-Term Assets	$54.15M	$61.07M	$32.87M
Total Long-Term Assets	$6.738M	$5.942M	$6.265M
Total Assets	$60.89M	$67.01M	$39.14M
YoY Change	73.92%	71.23%	126.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$973.0K	$1.076M	$575.0K
YoY Change	37.43%	87.13%	91.67%
Accrued Expenses	$3.869M	$2.817M	$1.766M
YoY Change	81.13%	59.51%	26.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$188.0K	$186.0K	$96.00K
YoY Change	27.03%	93.75%	-98.45%
Total Short-Term Liabilities	$5.114M	$4.163M	$2.616M
YoY Change	62.35%	59.14%	-70.27%
LONG-TERM LIABILITIES
Long-Term Debt	$1.081M	$1.129M	$6.900M
YoY Change	-84.99%	-83.64%	590.0%
Other Long-Term Liabilities	$7.300M	$7.400M	$1.400M
YoY Change	421.43%	428.57%
Total Long-Term Liabilities	$8.423M	$8.492M	$8.288M
YoY Change	-2.46%	2.46%	728.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.114M	$4.163M	$2.616M
Total Long-Term Liabilities	$8.423M	$8.492M	$8.288M
Total Liabilities	$13.54M	$12.66M	$10.90M
YoY Change	14.87%	16.06%	10.14%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock			$208.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$47.40M	$54.40M	$28.20M
YoY Change
Total Liabilities & Shareholders Equity	$60.89M	$67.01M	$39.14M
YoY Change	73.92%	71.23%	126.22%

Cashflow Statement

Concept	2013 Q3	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$8.123M	-$7.077M	-$6.309M
YoY Change	38.83%	12.17%	43.58%
Depreciation, Depletion And Amortization	$200.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	100.0%
Cash From Operating Activities	-$6.300M	-$4.900M	-$4.800M
YoY Change	85.29%	2.08%	33.33%
INVESTING ACTIVITIES
Capital Expenditures	-$1.000M	-$200.0K	-$400.0K
YoY Change		-50.0%	300.0%
Acquisitions
YoY Change
Other Investing Activities	$300.0K	$500.0K	$1.700M
YoY Change	-115.0%	-70.59%	0.0%
Cash From Investing Activities	-$800.0K	$300.0K	$1.400M
YoY Change	-60.0%	-78.57%	-22.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	300.0K	500.0K
YoY Change	-100.0%	-40.0%	-89.8%
NET CHANGE
Cash From Operating Activities	-6.300M	-4.900M	-4.800M
Cash From Investing Activities	-800.0K	300.0K	1.400M
Cash From Financing Activities	0.000	300.0K	500.0K
Net Change In Cash	-7.100M	-4.300M	-2.900M
YoY Change	47.92%	48.28%	-193.55%
FREE CASH FLOW
Cash From Operating Activities	-$6.300M	-$4.900M	-$4.800M
Capital Expenditures	-$1.000M	-$200.0K	-$400.0K
Free Cash Flow	-$5.300M	-$4.700M	-$4.400M
YoY Change	55.88%	6.82%	25.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4500000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3800000	shares
CY2013Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	812000	USD
CY2012Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	196000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	972000	USD
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1076000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1659000	USD
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2817000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2978000	USD
CY2013Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3403000	USD
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	173909000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	122514000	USD
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1200000	USD
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1100000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2000000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1900000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10600000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	155000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	372000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	199000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	20000	USD
	us-gaap	Interest Paid InterestPaid	150000	USD
	us-gaap	Interest Paid InterestPaid	18000	USD
	us-gaap	Interest Paid InterestPaid	20000	USD
	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	-449000	USD
CY2012Q4	us-gaap	Assets Assets	29429000	USD
CY2013Q2	us-gaap	Assets Assets	67013000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	23389000	USD
	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	0	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	61071000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	71000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	22000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	59039000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20250000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39490000	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30327000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9163000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	59039000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	38789000	USD
CY2013Q2	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	249000	USD
CY2012Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	1494000	USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	38833334	shares
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20985192	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25700286	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20985192	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25700286	shares
CY2013Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	257000	USD
CY2012Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	210000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, and certificates of deposit. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company’s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high quality cash equivalents such as money market funds or certificates of deposit.</font></div></div>
	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	0	USD
CY2013Q2	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	0	USD
CY2012Q2	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	0	USD
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	84000	USD
CY2013Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	84000	USD
CY2013Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1363000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1405000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	23100000	USD
CY2013Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	27300000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4174000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	372000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	425000	USD
CY2013Q2	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	119808000	USD
CY2012Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	104797000	USD
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2013Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	8600000	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	596000	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-1245000	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-1743000	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-13033000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	38000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	20000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3609000	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2264000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41208000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4265000	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2151000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1095000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	104000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-156000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1116000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	490000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4264000	USD
	us-gaap	Increase Decrease In Notes Receivable Related Parties IncreaseDecreaseInNotesReceivableRelatedParties	0	USD
	us-gaap	Increase Decrease In Notes Receivable Related Parties IncreaseDecreaseInNotesReceivableRelatedParties	350000	USD
	us-gaap	Increase Decrease In Notes Receivable Related Parties IncreaseDecreaseInNotesReceivableRelatedParties	0	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-617000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-813000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1015000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-535000	USD
CY2013Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	10000	USD
CY2012Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	12000	USD
CY2013Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1771000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	18000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2013Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	5249000	USD
CY2012Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	5085000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	11502000	USD
CY2013Q2	us-gaap	Liabilities Liabilities	12655000	USD
CY2012Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29429000	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	67013000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2919000	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4163000	USD
CY2012Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1400000	USD
CY2013Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1300000	USD
CY2012Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8583000	USD
CY2013Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8492000	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	204000	USD
CY2013Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	186000	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1178000	USD
CY2013Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1129000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	607000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	169787000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	49295000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	679000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9035000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	971000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-101713000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-11477000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10449000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-7077000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11151000	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-6309000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-119768000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15011000	USD
CY2013Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-583000	USD
CY2012Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-15011000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-11151000	USD
	us-gaap	Operating Expenses OperatingExpenses	130744000	USD
	us-gaap	Operating Expenses OperatingExpenses	15645000	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	6891000	USD
	us-gaap	Operating Expenses OperatingExpenses	12179000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	7301000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15111000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	8215000	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6301000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7069000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11118000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-122806000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	709000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2013Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	114000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	-21000	USD
CY2012Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	434000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	100000	USD
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2455000	USD
CY2012Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-33000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	4000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	505000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	120000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	13282000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8366000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1114000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	274000	USD
	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	113000	USD
	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.00	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.00	shares
CY2013Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2013Q2	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	907000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	67743000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	49416000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2013Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	535000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	91861000	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	3479000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	50000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	50000	USD
CY2013Q2	us-gaap	Profit Loss ProfitLoss	-7077000	USD
	us-gaap	Profit Loss ProfitLoss	-120351000	USD
	us-gaap	Profit Loss ProfitLoss	-11151000	USD
	us-gaap	Profit Loss ProfitLoss	-15011000	USD
CY2012Q2	us-gaap	Profit Loss ProfitLoss	-6309000	USD
CY2013Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	668000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	636000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6040000	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5942000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	47000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	456000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	51000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	47000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	550000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	74000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	89536000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11380000	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5037000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8570000	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4740000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1629000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2013Q2	us-gaap	Revenue From Grants RevenueFromGrants	232000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	7938000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	534000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	1061000	USD
CY2012Q2	us-gaap	Revenue From Grants RevenueFromGrants	590000	USD
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
	us-gaap	Share Based Compensation ShareBasedCompensation	1905000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2027000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10571000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	11.46
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	1500000	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2859887	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.62
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1200000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	4619	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	815250	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.31
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	62400000	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3752413	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4476177	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.34
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.78
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.71
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.25
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	46100000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	1654000	USD
	us-gaap	Stock Issued During Period Shares Employee Stock Ownership Plan StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan	28227	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4600000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	86867	shares
	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	176000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	48916000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2027000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	323000	USD
CY2013Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	54358000	USD
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17927000	USD
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25701354	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q2	dei	Entity Public Float EntityPublicFloat	342253457	USD
	dei	Entity Registrant Name EntityRegistrantName	NEWLINK GENETICS CORP
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4200000	USD
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2300000	USD
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25620566	shares
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20684944	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20649045	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24745380	shares
CY2012Q4	nlnk	Cash And Cash Equivalents Excluding Certificates Of Deposit CashAndCashEquivalentsExcludingCertificatesOfDeposit	20250000	USD
CY2013Q2	nlnk	Cash And Cash Equivalents Excluding Certificates Of Deposit CashAndCashEquivalentsExcludingCertificatesOfDeposit	59039000	USD
	nlnk	Design Build Agreement Story Construction Cost DesignBuildAgreementStoryConstructionCost	1000000	USD
	nlnk	Design Build Agreement Story Construction Square Feet DesignBuildAgreementStoryConstructionSquareFeet	11800
	nlnk	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition In Years EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognitionInYears	2.9
	nlnk	Forgiveness Of Notes Receivable From Related Parties ForgivenessOfNotesReceivableFromRelatedParties	0	USD
	nlnk	Forgiveness Of Notes Receivable From Related Parties ForgivenessOfNotesReceivableFromRelatedParties	350000	USD
	nlnk	Forgiveness Of Notes Receivable From Related Parties ForgivenessOfNotesReceivableFromRelatedParties	0	USD
	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	-435000	USD
	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	107000	USD
	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	-130000	USD
CY2013Q2	nlnk	Intrinsic Value Price Per Share Base IntrinsicValuePricePerShareBase	19.72
CY2013Q2	nlnk	Intrinsic Value Unvested IntrinsicValueUnvested	16300000	USD
CY2012Q4	nlnk	Lab Equipment LabEquipment	3297000	USD
CY2013Q2	nlnk	Lab Equipment LabEquipment	3428000	USD
	nlnk	Noncash Issuance Of Common Stock Dividend To Preferred Shareholders NoncashIssuanceOfCommonStockDividendToPreferredShareholders	0	USD
	nlnk	Noncash Issuance Of Common Stock Dividend To Preferred Shareholders NoncashIssuanceOfCommonStockDividendToPreferredShareholders	0	USD
	nlnk	Noncash Issuance Of Common Stock Dividend To Preferred Shareholders NoncashIssuanceOfCommonStockDividendToPreferredShareholders	6000	USD
	nlnk	Reduction Of Ipo Offering Costs ReductionOfIpoOfferingCosts	0	USD
	nlnk	Reduction Of Ipo Offering Costs ReductionOfIpoOfferingCosts	158000	USD
	nlnk	Reduction Of Ipo Offering Costs ReductionOfIpoOfferingCosts	0	USD
CY2013Q2	nlnk	Royalty Obligation Payable Noncurrent RoyaltyObligationPayableNoncurrent	6000000	USD
CY2012Q4	nlnk	Royalty Obligation Payable Noncurrent RoyaltyObligationPayableNoncurrent	6000000	USD
CY2013Q2	nlnk	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Vesting Term In Years ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageVestingTermInYears	7.3
CY2013Q2	nlnk	Share Based Compensation Shares Authorized Under Stock Option Plans Exercisable Options Weighted Average Vesting Term In Years ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisableOptionsWeightedAverageVestingTermInYears	6.4
CY2013Q2	nlnk	State Research And Development Credit Receivable StateResearchAndDevelopmentCreditReceivable	436000	USD
CY2012Q4	nlnk	State Research And Development Credit Receivable StateResearchAndDevelopmentCreditReceivable	542000	USD
CY2012Q4	nlnk	Total Leasehold Improvements And Equipment TotalLeaseholdImprovementsAndEquipment	9018000	USD
CY2013Q2	nlnk	Total Leasehold Improvements And Equipment TotalLeaseholdImprovementsAndEquipment	9345000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001126234

Files In Submission

Name	View Source	Status
0001126234-13-000114-index-headers.html	Edgar Link	pending
0001126234-13-000114-index.html	Edgar Link	pending
0001126234-13-000114.txt	Edgar Link	pending
0001126234-13-000114-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
logo20130630.jpg	Edgar Link	pending
newlinkphase7remodelp_image1.jpg	Edgar Link	pending
newlinkphase7remodelp_image4.jpg	Edgar Link	pending
newlinkphase7remodelp_image8.jpg	Edgar Link	pending
nlnk-20130630.xml	Edgar Link	completed
nlnk-20130630.xsd	Edgar Link	pending
nlnk-20130630x10q.htm	Edgar Link	pending
nlnk-20130630xex101.htm	Edgar Link	pending
nlnk-20130630xex102.htm	Edgar Link	pending
nlnk-20130630xex311.htm	Edgar Link	pending
nlnk-20130630xex312.htm	Edgar Link	pending
nlnk-20130630xex321.htm	Edgar Link	pending
nlnk-20130630_cal.xml	Edgar Link	unprocessable
nlnk-20130630_def.xml	Edgar Link	unprocessable
nlnk-20130630_lab.xml	Edgar Link	unprocessable
nlnk-20130630_pre.xml	Edgar Link	unprocessable
nlnk20130630ex102image1.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUMO
Lumos Pharma Inc Stock $lumo

2013 Q3 Form 10-Q Financial Statement

#000112623413000114 Filed on August 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO Lumos Pharma Inc Stock $lumo

2013 Q3 Form 10-Q Financial Statement

#000112623413000114 Filed on August 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO
Lumos Pharma Inc Stock $lumo